Literature DB >> 23032109

Clinical utility gene card for: familial polycythaemia vera.

Kais Hussein1, Galit Granot, Ofer Shpilberg, Hans Kreipe.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23032109      PMCID： PMC3658196          DOI： 10.1038/ejhg.2012.216

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN： 1018-4813            Impact factor:   4.246


× No keyword cloud information.
  25 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.

Authors:  Cécile Saint-Martin; Gwendoline Leroy; François Delhommeau; Gérard Panelatti; Sabrina Dupont; Chloé James; Isabelle Plo; Dominique Bordessoule; Christine Chomienne; André Delannoy; Alain Devidas; Martine Gardembas-Pain; Françoise Isnard; Yves Plumelle; Olivier Bernard; William Vainchenker; Albert Najman; Christine Bellanné-Chantelot
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

3.  Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation.

Authors:  Elena Albiero; Marco Ruggeri; Stefania Fortuna; Martina Bernardi; Silvia Finotto; Domenico Madeo; Francesco Rodeghiero
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

4.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Elisa Rumi; Ashot Harutyunyan; Francesco Passamonti; Daniela Pietra; Cristiana Pascutto; Tiina Berg; Roland Jäger; Emma Hammond; Mario Cazzola; Robert Kralovics
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

5.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Authors:  Amy V Jones; Andrew Chase; Richard T Silver; David Oscier; Katerina Zoi; Y Lynn Wang; Holger Cario; Heike L Pahl; Andrew Collins; Andreas Reiter; Francis Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

6.  A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors:  Outi Kilpivaara; Semanti Mukherjee; Alison M Schram; Martha Wadleigh; Ann Mullally; Benjamin L Ebert; Adam Bass; Sachie Marubayashi; Adriana Heguy; Guillermo Garcia-Manero; Hagop Kantarjian; Kenneth Offit; Richard M Stone; D Gary Gilliland; Robert J Klein; Ross L Levine
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

7.  JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Authors:  Kais Hussein; Oliver Bock; Katharina Theophile; Nils von Neuhoff; Thomas Buhr; Jerome Schlué; Guntram Büsche; Hans Kreipe
Journal:  Exp Hematol       Date:  2009-07-17       Impact factor: 3.084

8.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

9.  Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

Authors:  Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Tamara Weiss; Torsten Haferlach; Claudia Haferlach
Journal:  Ann Hematol       Date:  2009-05-05       Impact factor: 3.673

Review 10.  Clinical and hematological presentation of children and adolescents with polycythemia vera.

Authors:  Holger Cario; Mary Frances McMullin; Heike L Pahl
Journal:  Ann Hematol       Date:  2009-05-26       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.